Video

Dr. Advani Discusses Outcomes in ALCL

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses outcomes for patients with anaplastic large-cell lymphoma.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses outcomes for patients with anaplastic large-cell lymphoma (ALCL).

Though the prognosis for patients with ALK-positive ALCL is better than those with ALK-negative ALCL, the International Prognostic Index (IPI) remains an important factor. Patients with high IPI will not do as well as patients with low IPI, regardless of whether they are ALK-positive or ALK-negative. In fact, Advani says, all ALCL patients, treated with all regimens (CHOP chemotherapy and etoposide-containing chemotherapy) do better than other T-cell lymphoma patients. Patients treated with contemporary chemotherapy regimens containing etoposide such as CHOE, EPOCH, and Japanese regimen all demonstrate the highest outcomes, some as high as 70%, Advani says. Even in transplant studies, ALCL presents better outcomes. This begs the question as to whether the disease type or the treatment regimens trigger such robust results.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School